Simoa® Immunoassays Enable Ultrasensitive Detection of Blood-Based Biomarkers Associated with Alzheimer’s Disease
Publication Brief
Quanterix’s Simoa® ultrasensitive digital technology can reliably quantify blood-based biomarkers associated with Alzheimer's disease at femtogram-level concentrations – far below the standard Lower Limit of Quantification (LLOQ) of typical immunoassays. This technology supports researchers in transforming our understanding of AD pathology, opens new doors for diagnostic and prognostic AD work-up, and has the potential to improve clinical trial design and outcomes. Download our publication brief to learn more and to view a sampling of peer-reviewed studies using Simoa® technology for AD research.